Surprising result for the treatment of moderate to severe AD with lebrikizumab
During this MEDtalk, Andrew Blauvelt discusses the recently published 52-week data on the effectiveness and safety of lebrikizumab in treating moderate to severe atopic dermatitis (AD). The study reveals unexpectedly positive results, showing sustained improvements in all measured outcomes.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
